Preparation and Characterization of Two Polymorphs of (3aRS,4RS,7RS,7aSR)-2-(Tricyclo[3.3.1.13,7]decan-1-yl)-4,5,6,7-tetrahydro-4,7-eposyisoindoline-1,3-dione (SU2162) with PXRD and DSC
Read full paper at:
http://www.scirp.org/journal/PaperInformation.aspx?PaperID=53119#.VLXOUMnQrzE
http://www.scirp.org/journal/PaperInformation.aspx?PaperID=53119#.VLXOUMnQrzE
Author(s)
Wenfei Chen, Zaiyou Tan*, Lin Luo, Ruisi Yan, Hui Yang, Chunmei Tong, Yuqing Huang, Tingyu Huang, Yang Yang, Ruonan Wang
ABSTRACT
Objective:
To develop the characterization of the polymorphs and the best
preparation method of two forms of the title compound (SU2162). After
SU2162 was prepared in accordance with the patent process, the crystal
form I was recrystallized by ethyl acetate and the crystal form II was
obtained by the recrystal in acetone. And the two crystal forms were
characterized with differential scanning calorimetry (DSC) and X-ray
powder diffraction (PXRD). The melting point of crystal form I
(triclinic) is at 158°C, and the melting point of crystal form II
(monoclinic) is at 163°C. The PXRD studies of the two crystalline
samples indicate that they have the distinct diffraction patterns. The
method herein can be stably prepared for the two crystal forms of the
title compound.
Cite this paper
References
Chen,
W. , Tan, Z. , Luo, L. , Yan, R. , Yang, H. , Tong, C. , Huang, Y. ,
Huang, T. , Yang, Y. and Wang, R. (2015) Preparation and
Characterization of Two Polymorphs of
(3aRS,4RS,7RS,7aSR)-2-(Tricyclo[3.3.1.13,7]decan-1-yl)-4,5,6,7-tetrahydro-4,7-eposyisoindoline-1,3-dione (SU2162) with PXRD and DSC. Advances in Materials Physics and Chemistry, 5, 16-21. doi: 10.4236/ampc.2015.51003.
| [1] | American Cancer Society (2014) Cancer Facts & Figures 2014. American Cancer Society, Atlanta. http://www.cancer.org/research/cancerfactsstatistics/cancerfactsfigures2014/index |
| [2] | Stewart, B.W. and Wild, C.P. (2014) World Cancer Report 2014. International Agency for Research on Cancer, France. http://www.esmo.org/Oncology-News/World-Cancer-Report-2014 |
| [3] | O’Callaghan, T. (2011) Introduction: The Prevention Agenda. Nature, 471, S2-S4. http://www.nature.com/nature/journal/v471/n7339_supp/fig_tab/471S2a_F1.html http://dx.doi.org/10.1038/471S2a |
| [4] | Tan, Z. (2008) Chinese Patent No. 2007100297361. |
| [5] | Tan,
Z., Luo, L., Zhu, E., Yan, R. and Lin, Z. (2010)
(3aRS,4SR,7RS,7aSR)-2-(Tricyclo-[3.3.1.1]decan-1-yl)-4,5,6,7-
tet-ra-hydro-4,7-epoxyisoindoline-1,3-dione. Acta Crystallographica
Section E, 66, Article ID: o1374. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2979399/ http://dx.doi.org/10.1107/S1600536810016971 |
| [6] | Tan,
Z.Y., Luo, L., Zhu, E.J., Lin, Z.H., Yan, R.S., Zhang, H. and Liang, K.
(2010) Preparation and X-Ray Diffraction Analysis of a New Crystal Form
of
(3aRS,4RS,7RS,7aSR)-2-(Tricyclo[3.3.1.13,7]decan-1-yl)-4,5,6,7-tetrahydro-4,7-epoxyisoin-doline-1,3-dione—A
Novel Anticancer Compound. Journal of Guangdong Pharmaceutical College,
26, 441-444. http://www.cqvip.com/QK/90465A/201006/37126978.html |
| [7] | Tan, Z.Y., Yan, R.S., Lu, J.H., Ye, Q., Guan, W.S., Zhang, X.L. and Yang, H. (2012) Determination of (3aRS,4SR, 7RS,7aSR)-2-(Tricyclo-[3.3.1.13,7]decan-1-yl)-4,5,6,7-tetrahydro-4,7-epoxyisoindoline-1,3-dione (SU2162) in Rat Plasma by High-Performance Liquid Chromatography with UV Detection. The Analytical Chemistry, 11, 347-352. |
| [8] | Tan,
Z., Yang, H., Yan, R., Liu, R., Li, X., Ye, Q., Guan, W., Zhang, X.,
Huang, Y., Tong, C. and Chen, W. (2014) Pharmacokinetics and Tissue
Distribution of SU2162, a Novel Anticancer Drug, after Intravenous
Administration in Rats. Journal of Pharmaceutical Technology and Drug
Research, 3, 1-6. http://www.hoajonline.com/jptdr/2050-120X/3/1 http://dx.doi.org/10.7243/2050-120X-3-1 |
| [9] | Huang,
Y.Q., Tan, Z.Y., Luo, L., Yang, H., Tong, C.M., Chen, W.F., Huang, T.Y.
and Liu, R.L. (2014) The Polymorphism and Transformation of
(3aRS,4RS,7RS,7aSR)-2-(Tricyclo[3.3.1.13,7]decan-1-yl)-4,5,6,7-tetrahydro-4,7-eposyi-soindoline-1,3-dione
(SU2162)—A Novel Anticancer Compound. Journal of Crystallization
Process and Technology, 4, 27-30. http://dx.doi.org/10.4236/jcpt.2014.41004 |
| [10] | Sinko, P.J. (2006) Martin’s Physical Pharmacy and Pharmaceutical Sciences. 5th Edition, Lippincott Williams & Wilkins, Philadelphia. |
| [11] | Brittain, H.G. (1995) Physical Characterization of Pharmaceutical Solid. Vol. 70, Marcel Dekker, New York. http://dx.doi.org/10.1201/b14204 eww150114lx |
评论
发表评论